Quality of life among symptomatic compared to PSA-detected prostate cancer survivors - results from a UK wide patient-reported outcomes study

Table 2 Age, stage, Gleason score and treatment received for PSA-detected compared to symptomatic prostate cancer survivors^#

Respondent characteristics	Proportion PSA-detected ^a (n = 11,210)	Proportion symptomatic ^a (n = 21,378)	Adjusted odds ratio (95% CI) of being symptomatic compared to PSA-detected ^b (n = 32,588)
All respondents (n = 32,588)	34.4%	65.6%	–
Age at diagnosis
< 54	36.3%	63.7%	1.00
55-64	35.0%	65.0%	0.92 (0.81-1.05)
65-74	35.3%	64.7%	0.83 (0.72-0.95)*
75+	31.8%	68.2%	0.87 (0.75-1.01)
Stage
I/II	38.3%	61.7%	1.00
III	32.2%	67.8%	1.20 (1.12-1.28)**
IV	18.5%	81.5%	2.03 (1.82-2.27)**
Gleason score
2-6	37.0%	63.0%	1.00
7	37.3%	62.7%	0.86 (0.80-0.92)**
8-10	25.4%	74.6%	1.12 (1.03-1.22)*
Treatment type ^c
Any surgery	36.7%	63.3%	1.05 (0.98-1.13)
Any EBRT	32.7%	67.3%	1.04 (0.98-1.11)
Any brachytherapy	42.4%	57.6%	0.77 (0.70-0.85)**
Any ADT	29.4%	70.6%	1.22 (1.14-1.30)**
Any systemic	17.7%	82.3%	1.64 (1.43-1.89)**
Any other	37.1%	62.9%	1.00 (0.92-1.09)
Monitoring only	37.4%	62.6%	1.05 (0.96-1.16)

Notes
EBRT External Beam Radiotherapy, ADT Androgen Deprivation Therapy, Systemic - Chemotherapy/Abiraterone/Enzalutamide # Alive 18-42 months after diagnosis, CI: Confidence interval
* p < 0.05, ** p < 0.001
^a Denominator excludes other and missing method of presentation
^b Determined using multivariable logistic regression adjusted for other variables in the table plus nation, deprivation, number of comorbidities, BMI, ethnicity, marital status and employment status. An odds ratio greater than 1 represents a greater odds than the baseline (i.e. first) group of being symptomatic compared to PSA-detected
^c Men may have more than one type of treatment. Odds ratios for treatment type have a reference category of not receiving that treatment type (i.e. No surgery, No EBRT etc.)

ISSN: 1471-2407